Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Addeo

Showing results (71-80 of 224) with videos related to

Pageof 23
Sort By:
Case Reports in Oncology|March 29, 2021
Vertebral Metastasis Treated by Vertebroplasty, a Cause of Respiratory Failure: Case Report and Literature ReviewMathieu Chevallier, Chloé Chevallier-Lugon, Alex Friedlaender, et al.
Critical Reviews in Oncology/Hematology|February 21, 2018
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenarioAlfredo Addeo, Fabrizio Tabbò, Tim Robinson, et al.
Frontiers in Oncology|May 7, 2019
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-AnalysisAlfredo Addeo, Giuseppe Luigi Banna, Giulio Metro, et al.
Therapeutic Advances in Drug Safety|April 15, 2021
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative reviewLaure Thouvenin, Timothée Olivier, Giuseppe Banna, et al.
The Lancet. Respiratory Medicine|August 19, 2024
Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON studyMolly S C Li, Stephanie P L Saw, Alfredo Addeo
Frontiers in Medicine|June 13, 2022
First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond ChemoimmunotherapyEmilio Francesco Giunta, Alfredo Addeo, Alessio Rizzo, et al.
Cancer Epidemiology|July 29, 2022
Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questionsDaniele Frisone, Jose Sandoval, Alex Friedlaender, et al.
Current Oncology Reports|August 30, 2023
Cellular Therapy in NSCLC: Between Myth and RealityMartina Imbimbo, Laureline Wetterwald, Alex Friedlaender, et al.
Critical Reviews in Oncology/Hematology|June 3, 2020
A BRAF new worldDaniele Frisone, Alex Friedlaender, Umberto Malapelle, et al.
Critical Reviews in Oncology/Hematology|June 4, 2021
TMB or not TMB as a biomarker: That is the questionAlfredo Addeo, Alex Friedlaender, Giuseppe L Banna, et al.
Pageof 23

Showing results (71-80 of 224) with videos related to

Sort By:
Pageof 23
Case Reports in Oncology|March 29, 2021
Vertebral Metastasis Treated by Vertebroplasty, a Cause of Respiratory Failure: Case Report and Literature ReviewMathieu Chevallier, Chloé Chevallier-Lugon, Alex Friedlaender, et al.
Critical Reviews in Oncology/Hematology|February 21, 2018
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenarioAlfredo Addeo, Fabrizio Tabbò, Tim Robinson, et al.
Frontiers in Oncology|May 7, 2019
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-AnalysisAlfredo Addeo, Giuseppe Luigi Banna, Giulio Metro, et al.
Therapeutic Advances in Drug Safety|April 15, 2021
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative reviewLaure Thouvenin, Timothée Olivier, Giuseppe Banna, et al.
The Lancet. Respiratory Medicine|August 19, 2024
Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON studyMolly S C Li, Stephanie P L Saw, Alfredo Addeo
Frontiers in Medicine|June 13, 2022
First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond ChemoimmunotherapyEmilio Francesco Giunta, Alfredo Addeo, Alessio Rizzo, et al.
Cancer Epidemiology|July 29, 2022
Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questionsDaniele Frisone, Jose Sandoval, Alex Friedlaender, et al.
Current Oncology Reports|August 30, 2023
Cellular Therapy in NSCLC: Between Myth and RealityMartina Imbimbo, Laureline Wetterwald, Alex Friedlaender, et al.
Critical Reviews in Oncology/Hematology|June 3, 2020
A BRAF new worldDaniele Frisone, Alex Friedlaender, Umberto Malapelle, et al.
Critical Reviews in Oncology/Hematology|June 4, 2021
TMB or not TMB as a biomarker: That is the questionAlfredo Addeo, Alex Friedlaender, Giuseppe L Banna, et al.
Pageof 23